Linked Life Data

19719716

Source:http://linkedlifedata.com/resource/pubmed/id/19719716

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2009-9-1
pubmed:abstractText
Exenatide is an incretin mimetic licensed for treatment of Type 2 diabetes poorly controlled despite maximally tolerated doses of oral therapy. Similar in structure to the natural incretin hormone glucagon-like peptide 1 (GLP-1), it helps restore underlying pathophysiological abnormalities.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1464-5491
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
935-8
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
pubmed:affiliation
Department of Diabetes and Endocrinology, North Manchester General Hospital, Manchester, M85RB, UK.
pubmed:publicationType
Journal Article, Case Reports